Breast Cancer Clinical Trial
Official title:
The Immune Response of Breast Cancer Patients Treated With Levobupivacaine Using Paravertebral or Superficial Chest Blocks
The use of regional anesthesia in breast surgery improves the postoperative outcome, reduces the development of infection, and weakens the perioperative immunosuppressive response associated with the response to surgical stress. The investigators hypothesize that the use of propofol / paravertebral anesthesia and analgesia will be accompanied by a decrease in serum proinflammatory cytokines and/or an increase in anti-inflammatory cytokines compared to propofol / PECS 2 anesthesia and analgesia. The research will be on 100 respondents divided into two groups. 0.5% levobupivacaine will be administered to both groups. Serum concentrations of pro- and anti-inflammatory cytokines, and lymphocyte subpopulations 1h before, 24h, and 48h after surgery will be measured. The investigators aim to compare the effect of propofol / paravertebral and propofol / PECS 2 anesthesia and analgesia on serum perioperative values of pro-inflammatory and anti-inflammatory cytokines to standardize protocols and apply the best method of perioperative analgesia in breast cancer surgery.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | December 2025 |
Est. primary completion date | May 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - quadrantectomy with equilateral axillary lymphadenectomy - anesthesia preoperative status (American Society of Anesthesiologists (ASA)) 1 and 2 Exclusion Criteria: - patient rejection - ASA> 3 - contraindication for local anesthetic - contraindications for planned regional anesthesia and analgesia - immunosuppressive therapy including corticosteroids - acute infection - history of chronic opioid use - presence of autoimmune disease - obese definite body mass index BMI) greater than 29.9 kg/m2 |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Rijeka |
Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, McDonald PG, Stefanek M, Sood AK. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer. 2006 Mar;6(3):240-8. doi: 10.1038/nrc1820. — View Citation
Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA, Nicholas RW, Suva LJ. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res. 2002 Oct 1;62(19):5571-9. — View Citation
Blanco R, Fajardo M, Parras Maldonado T. Ultrasound description of Pecs II (modified Pecs I): a novel approach to breast surgery. Rev Esp Anestesiol Reanim. 2012 Nov;59(9):470-5. doi: 10.1016/j.redar.2012.07.003. Epub 2012 Aug 29. — View Citation
Brown DL, Ransom DM, Hall JA, Leicht CH, Schroeder DR, Offord KP. Regional anesthesia and local anesthetic-induced systemic toxicity: seizure frequency and accompanying cardiovascular changes. Anesth Analg. 1995 Aug;81(2):321-8. doi: 10.1097/00000539-199508000-00020. — View Citation
Deegan CA, Murray D, Doran P, Moriarty DC, Sessler DI, Mascha E, Kavanagh BP, Buggy DJ. Anesthetic technique and the cytokine and matrix metalloproteinase response to primary breast cancer surgery. Reg Anesth Pain Med. 2010 Nov-Dec;35(6):490-5. doi: 10.1097/AAP.0b013e3181ef4d05. — View Citation
Desborough JP. The stress response to trauma and surgery. Br J Anaesth. 2000 Jul;85(1):109-17. doi: 10.1093/bja/85.1.109. No abstract available. — View Citation
Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995 Feb;1(2):149-53. doi: 10.1038/nm0295-149. — View Citation
Homburger JA, Meiler SE. Anesthesia drugs, immunity, and long-term outcome. Curr Opin Anaesthesiol. 2006 Aug;19(4):423-8. doi: 10.1097/01.aco.0000236143.61593.14. — View Citation
Karmakar MK. Thoracic paravertebral block. Anesthesiology. 2001 Sep;95(3):771-80. doi: 10.1097/00000542-200109000-00033. No abstract available. — View Citation
Kulhari S, Bharti N, Bala I, Arora S, Singh G. Efficacy of pectoral nerve block versus thoracic paravertebral block for postoperative analgesia after radical mastectomy: a randomized controlled trial. Br J Anaesth. 2016 Sep;117(3):382-6. doi: 10.1093/bja/aew223. — View Citation
Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016 Sep;37(9):11553-11572. doi: 10.1007/s13277-016-5098-7. Epub 2016 Jun 3. — View Citation
Mrakovcic-Sutic I, Bacic D, Golubovic S, Bacic R, Marinovic M. Cross-talk between NKT and regulatory T cells (Tregs) in modulation of immune response in patients with colorectal cancer following different pain management techniques. Coll Antropol. 2011 Sep;35 Suppl 2:57-60. — View Citation
Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev. 2006 Oct;17(5):325-37. doi: 10.1016/j.cytogfr.2006.07.002. Epub 2006 Aug 22. — View Citation
Rao VS, Dyer CE, Jameel JK, Drew PJ, Greenman J. Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). Oncol Rep. 2006 Jan;15(1):179-85. doi: 10.3892/or.15.1.179. — View Citation
Sacerdote P, Bianchi M, Gaspani L, Manfredi B, Maucione A, Terno G, Ammatuna M, Panerai AE. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg. 2000 Jun;90(6):1411-4. doi: 10.1097/00000539-200006000-00028. — View Citation
Salo M. Effects of anaesthesia and surgery on the immune response. Acta Anaesthesiol Scand. 1992 Apr;36(3):201-20. doi: 10.1111/j.1399-6576.1992.tb03452.x. — View Citation
Schnabel A, Reichl SU, Kranke P, Pogatzki-Zahn EM, Zahn PK. Efficacy and safety of paravertebral blocks in breast surgery: a meta-analysis of randomized controlled trials. Br J Anaesth. 2010 Dec;105(6):842-52. doi: 10.1093/bja/aeq265. Epub 2010 Oct 14. Erratum In: Br J Anaesth. 2013 Sep;111(3):522. — View Citation
Segerstrom SC, Miller GE. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychol Bull. 2004 Jul;130(4):601-30. doi: 10.1037/0033-2909.130.4.601. — View Citation
Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biosci. 2008 May 1;13:5094-107. doi: 10.2741/3066. — View Citation
Tsuchiya Y, Sawada S, Yoshioka I, Ohashi Y, Matsuo M, Harimaya Y, Tsukada K, Saiki I. Increased surgical stress promotes tumor metastasis. Surgery. 2003 May;133(5):547-55. doi: 10.1067/msy.2003.141. — View Citation
Zura M, Kozmar A, Sakic K, Malenica B, Hrgovic Z. Effect of spinal and general anesthesia on serum concentration of pro-inflammatory and anti-inflammatory cytokines. Immunobiology. 2012 Jun;217(6):622-7. doi: 10.1016/j.imbio.2011.10.018. Epub 2011 Nov 3. — View Citation
* Note: There are 21 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in measured serum cytokines using an ELISA test after PVB. | Venous blood samples will be collected 1 hour before and 24 and 48 hours after surgery. Serum concentrations in picogram per milliliter of pro-inflammatory cytokines Il-1, Il-6, TNFa, and anti-inflammatory cytokine IL-10 will be analyzed using an ELISA test according to the manufacturer's instructions. | 1 hour before intervention to 48 hours after surgery | |
Primary | Change in measured serum cytokines using an ELISA test after PECS 2 block. | Venous blood samples will be collected 1 hour before and 24 and 48 hours after surgery. Serum concentrations picogram per milliliter of pro-inflammatory cytokines Il-1, Il-6, TNFa, and anti-inflammatory cytokine IL-10 will be analyzed using an ELISA test according to the manufacturer's instructions. | 1 hour before intervention to 48 hours after surgery | |
Primary | Change in cell number of individual lymphocyte subpopulations determined by flow cytometry technique (FACSCalibur) after PVB application. | Venous blood samples will be collected 1 hour before and 24 and 48 hours after surgery. Peripheral blood leukocytes (PBL) will be isolated using a fluorescence-activated single-cell sorting flow cytometry technique on the FACSCalibur Flow Cytometer machine. Flow cytometry is a laser-based technique that detects and analyzes the chemical and physical characteristics of cells or particles. Individual lymphocyte subpopulations: T lymphocytes (helper and cytotoxic), B lymphocytes, NK, Treg (FITC-CD4, APC-CD25, and PE-Foxp3 positive), and NKT cells will be analyzed and determined according to the manufacturer's instructions using specific cell marker antibodies. After gating density plots the results will be presented in the number of cells in a cubic millimeter of blood and compared using scatter graphs. | 1 hour before intervention to 48 hours after surgery | |
Primary | Change in cell number of individual lymphocyte subpopulations determined by flow cytometry technique (FACSCalibur) after PECS 2 block application. | Venous blood samples will be collected 1 hour before and 24 and 48 hours after surgery. Peripheral blood leukocytes (PBL) will be isolated using a fluorescence-activated single-cell sorting flow cytometry technique on the FACSCalibur Flow Cytometer machine. Flow cytometry is a laser-based technique that detects and analyzes the chemical and physical characteristics of cells or particles. Individual lymphocyte subpopulations: T lymphocytes (helper and cytotoxic), B lymphocytes, NK, Treg (FITC-CD4, APC-CD25, and PE-Foxp3 positive), and NKT cells will be analyzed and determined according to the manufacturer's instructions using specific cell marker antibodies. After gating density plots the results will be presented in the number of cells in a cubic millimeter of blood and compared using scatter graphs. | 1 hour before intervention to 48 hours after surgery | |
Secondary | Duration of postoperative analgesia after PVB application measured using visual analgesic scale (VAS). | Postoperatively the subjects will be monitored in a post-anesthesia care unit (PACU) room where visual analgesic scale (VAS) [from 0 (no pain) to 10 (worst imaginable pain) according to Rawal will be notified at arrival to PACU, 1 hour and 2 hours postoperatively. Then the participants will be transferred to the department where, during the first 24 hours, the VAS will be assessed every 3 hours. | 24 postoperative hours | |
Secondary | Duration of postoperative analgesia after PECS 2 block application measured using visual analgesic scale (VAS). | Postoperatively the subjects will be monitored in a post-anesthesia care unit (PACU) room where visual analgesic scale (VAS) [from 0 (no pain) to 10 (worst imaginable pain) according to Rawal will be notified at arrival to PACU, 1 hour and 2 hours postoperatively. Then the participants will be transferred to the department where, during the first 24 hours, the VAS will be assessed every 3 hours. | 24 postoperative hours | |
Secondary | The total dosage of analgesics in the postoperative period after the PVB application. | The investigators will measure the total dosage of non-steroidal anti-inflammatory drugs (in mg) or opioid (in mg) analgesics in the first 48 hours after the PVB application. | 48 postoperative hours | |
Secondary | The total dosage of analgesics in the postoperative period after the PECS 2 block application. | The investigators will measure the total dosage of non-steroidal anti-inflammatory drugs (in mg) or opioid (in mg) analgesics in the first 48 hours after the PECS 2 application. | 48 postoperative hours | |
Secondary | Mean atrial pressure change after the PVB. | Before induction, mean arterial pressure (in mmHg) will be recorded using standard perioperative noninvasive blood pressure measurements at the time of block application, 60 min after, and at the time of transfer to the operating room. After induction, mean arterial pressure values will be recorded every five minutes for the duration of the operation. Postoperatively, subjects will be monitored in a post-anesthesia room where mean arterial pressure will be monitored at arrival, 1 hour and 2 hours postoperatively. | From time of intervention to 2 hours postoperatively | |
Secondary | Mean atrial pressure change after the PECS 2 block. | Before induction, mean arterial pressure (in mmHg) will be recorded using standard perioperative noninvasive blood pressure measurements at the time of block application, 60 min after, and at the time of transfer to the operating room. After induction, mean arterial pressure values will be recorded every five minutes for the duration of the operation. Postoperatively, subjects will be monitored in a post-anesthesia room where mean arterial pressure will be monitored at arrival, 1 hour and 2 hours postoperatively. | From time of intervention to 2 hours postoperatively | |
Secondary | Change in the volume compensation of colloids after the PVB. | Total preoperative crystalloids infusions in milliliters will be recorded at the time of transfer to the operating room. Total intraoperative colloid infusions will be recorded at the end of the operation, before transfer to the PACU. Total postoperative crystalloids infusions will be recorded in PACU at the transfer to the department and after the first 24 hours at the department. The investigators will compare the difference between the two groups. | From the time of intervention to 24 hours postoperatively | |
Secondary | Change in the volume compensation of colloids after the PECS2 block. | Total preoperative colloid infusions in milliliters will be recorded at the time of transfer to the operating room. Total intraoperative colloid infusions will be recorded at the end of the operation, before transfer to the PACU. Total postoperative colloid infusions will be recorded in PACU at the transfer to the department and after the first 24h at the department. The investigators will compare the difference between the two groups. | From the time of intervention to 24 hours postoperatively | |
Secondary | Changes in heart rate values after the PVB. | Before induction heart rate (in beats per minute) will be recorded using standard perioperative ECG monitoring at the time of block application, 60 min after, and at the time of transfer to the operating room. After induction, heart rate values will be recorded every five minutes for the duration of the operation. Postoperatively, subjects will be monitored in a post-anesthesia room where heart rate will be monitored at arrival, 1 hour and 2 hours postoperatively. | From the time of intervention to 2 hours postoperatively | |
Secondary | Changes in heart rate values after the PECS 2 block. | Before induction heart rate (in beats per minute) will be recorded standard perioperative ECG monitoring at the time of block application, 60 min after, and at the time of transfer to the operating room. After induction, heart rate values will be recorded every five minutes for the duration of the operation. Postoperatively, subjects will be monitored in a post-anesthesia room where heart rate will be monitored at arrival, 1 hour and 2 hours postoperatively. | From the time of intervention to 2 hours postoperatively | |
Secondary | Change in the perioperative need for vasoactive drugs after PVB. | Total perioperative vasoactive drug applications in milligrams will be recorded at the end of the operation and before the transfer to the department. The investigators will compare the difference between the two groups in vasoactive drug application. | From the time of intervention to 2 hours postoperatively | |
Secondary | Change in the perioperative need for vasoactive drugs after PECS 2 block. | Total perioperative vasoactive drug applications in milligrams will be recorded at the end of the operation and before the transfer to the department. The investigators will compare the difference between the two groups in vasoactive drug application. | From the time of intervention to 2 hours postoperatively |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |